{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:49:20Z","timestamp":1781221760185,"version":"3.54.1"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Human papillomavirus type 58 (HPV-58) exists in a relatively high prevalence in certain parts of the world, including East Asia. This study examined the T-cell response to HPV-58 L1, E6, and E7 peptides among women with cleared infection, cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3, or invasive cervical cancer (ICC). Peptides found to be reactive in the<jats:italic>in vitro<\/jats:italic>peptide binding assay or mouse-stimulating study were tested with a gamma interferon (IFN-\u03b3) enzyme-linked immunospot (ELISPOT) assay to detect peptide-specific responses from the peripheral blood mononuclear cells (PBMC) collected from 91 HPV-58-infected women (32 with cleared infection, 16 CIN2, 15 CIN3, and 28 ICC). Four HLA-A11-restricted HPV-58 L1 peptides, located at amino acid positions 296 to 304, 327 to 335, 101 to 109, and 469 to 477, showed positive IFN-\u03b3 ELISPOT results and were mainly from women with cleared infection. Two HLA-A11-restricted E6 peptides (amino acid positions 64 to 72 and 94 to 102) and three HLA-A11-restricted E7 peptides (amino acid positions 78 to 86, 74 to 82, and 88 to 96) showed a positive response. A response to E6 and E7 peptides was mainly observed from subjects with CIN2 or above. One HLA-A2-restricted E6 peptide, located at amino acid position 99 to 107, elicited a positive response in two CIN2 subjects. One HLA-A24-restricted L1 peptide, located at amino acid position 468 to 476, also elicited a positive response in two CIN2 subjects. In summary, this study has identified a few immunogenic epitopes for HPV-58 E6 and E7 proteins. It is worthwhile to further investigate whether responses to these epitopes have a role in clearing an established cervical lesion.<\/jats:p>","DOI":"10.1128\/cvi.00105-10","type":"journal-article","created":{"date-parts":[[2010,7,29]],"date-time":"2010-07-29T06:25:47Z","timestamp":1280384747000},"page":"1315-1321","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer"],"prefix":"10.1128","volume":"17","author":[{"given":"Paul K. S.","family":"Chan","sequence":"first","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Liu","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. H.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Ngai","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo L. K.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pele","family":"Chong","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Man","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"},{"name":"Obstetrics and Gynaecology"},{"name":"Clinical Oncology"},{"name":"Biology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Vaccine Development and Research Center, National Health Research Institutes, Miaoli, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0002-9378(96)70110-2","volume":"175","year":"1996","unstructured":"Alexander, M., M. L. Salgaller, E. Celis, A. Sette, W. A. Barnes, S. A. Rosenberg, and M. A. Steller. 1996. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol.175:1586-1593.","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_2_3_2","first-page":"622","volume":"10","year":"2008","unstructured":"Alvarez-Salas, L. M. 2008. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr. Opin. Mol. Ther.10:622-628.","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/1097-0215(20001001)88:1<92::AID-IJC15>3.0.CO;2-E","volume":"88","year":"2000","unstructured":"Bontkes, H. J., T. D. de Gruijl, A. J. van den Muysenberg, R. H. Verheijen, M. J. Stukart, C. J. Meijer, R. J. Scheper, S. N. Stacey, M. F. Duggan-Keen, P. L. Stern, S. Man, L. K. Borysiewicz, and J. M. Walboomers. 2000. Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int. J. Cancer.88:92-98.","journal-title":"Int. J. Cancer."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2001.6205","volume":"82","year":"2001","unstructured":"Castellanos, M. R., R. L. Hayes, and M. A. Maiman. 2001. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Gynecol. Oncol.82:77-83.","journal-title":"Gynecol. Oncol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/(SICI)1096-9071(199910)59:2<232::AID-JMV18>3.0.CO;2-7","volume":"59","year":"1999","unstructured":"Chan, P. K., W. H. Li, M. Y. Chan, W. L. Ma, J. L. Cheung, and A. F. Cheng. 1999. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J. Med. Virol.59:232-238.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1179\/095741905X49098","volume":"16","year":"2005","unstructured":"Chan, P. K. 2005. Epidemiology of human papillomavirus in Asia: do HPV-52 and HPV-58 play a special role? Papillomavirus Rep.16:265-271.","journal-title":"Papillomavirus Rep."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.21299","volume":"118","year":"2006","unstructured":"Chan, P. K., T. H. Cheung, A. O. Tam, K. W. Lo, S. F. Yim, M. M. Yu, K. F. To, Y. F. Wong, J. L. Cheung, D. P. Chan, M. Hui, and M. Ip. 2006. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int. J. Cancer118:243-245.","journal-title":"Int. J. Cancer"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcv.2008.11.001","volume":"44","year":"2009","unstructured":"Chan, P. K., A. C. Luk, T. N. Luk, K. F. Lee, J. L. Cheung, K. M. Ho, and K. K. Lo. 2009. Distribution of human papillomavirus types in anogenital warts of men. J. Clin. Virol.44:111-114.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.4161\/cbt.8.21.9732","volume":"8","year":"2009","unstructured":"Chen, H. W., C. H. Leng, H. Y. Liu, W. F. Cheng, Y. W. Chang, P. Y. Wu, S. P. Lien, T. Y. Huang, S. K. Chiang, M. H. Lin, M. H. Tao, P. Chong, and S. J. Liu. 2009. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol. Ther.8:2025-2032.","journal-title":"Cancer Biol. Ther."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","year":"2003","unstructured":"Clifford, G. M., J. S. Smith, M. Plummer, N. Mu\u00f1oz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88:63-73.","journal-title":"Br. J. Cancer"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","volume":"110","year":"2006","unstructured":"Doorbar, J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.)110:525-541.","journal-title":"Clin. Sci. (Lond.)"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002620050265","volume":"42","year":"1996","unstructured":"Evans, C., S. Bauer, T. Grubert, C. Brucker, S. Baur, K. Heeg, H. Wagner, and G. B. Lipford. 1996. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother.42:151-160.","journal-title":"Cancer Immunol. Immunother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/eji.1830250935","volume":"25","year":"1995","unstructured":"Feltkamp, M. C., G. R. Vreugdenhil, M. P. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol.25:2638-2642.","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jnci\/91.6.506","volume":"91","year":"1999","unstructured":"Franco, E. L., T. E. Rohan, and L. L. Villa. 1999. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J. Natl. Cancer Inst.91:506-511.","journal-title":"J. Natl. Cancer Inst."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","year":"2007","unstructured":"FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356:1915-1927.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","year":"2007","unstructured":"Garland, S. M., M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. M. Harper, S. Leodolter, G. W. Tang, D. G. Ferris, M. Steben, J. Bryan, F. J. Taddeo, R. Railkar, M. T. Esser, H. L. Sings, M. Nelson, J. Boslego, C. Sattler, E. Barr, and L. A. Koutsky for the Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE) I Investigators. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356:1928-1943.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","year":"2006","unstructured":"Harper, D. M., E. L. Franco, C. M. Wheeler, A. B. Moscicki, B. Romanowski, C. M. Roteli-Martins, D. Jenkins, A. Schuind, S. A. Costa Clemens, and G. Dubin for the HPV Vaccine Study Group. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367:1247-1255.","journal-title":"Lancet"},{"key":"e_1_3_2_19_2","first-page":"1838","volume":"19","year":"2009","unstructured":"Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, S. H. van der Burg, and C. J. Melief. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.19:1838-1847.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_20_2","first-page":"3406","volume":"6","year":"2000","unstructured":"Muderspach, L., S. Wilczynski, L. Roman, L. Bade, J. Felix, L. A. Small, W. M. Kast, G. Fascio, V. Marty, and J. Weber. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res.6:3406-3416.","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(00)00125-6","volume":"19","year":"2000","unstructured":"Mu\u00f1oz, N. 2000. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol.19:1-5.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","year":"2003","unstructured":"Mu\u00f1oz, N., F. X. Bosch, S. de Sanjos\u00e9, R. Herrero, X. Castellsagu\u00e9, K. V. Shah, P. J. Snijders, and C. J. Meijer for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cancer. N. Engl. J. Med.348:518-527.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/315706","volume":"182","year":"2000","unstructured":"Nakagawa, M., D. P. Stites, S. Patel, S. Farhat, M. Scott, N. K. Hills, J. M. Palefsky, and A. B. Moscicki. 2000. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis.182:595-598.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_24_2","first-page":"4855","volume":"57","year":"1997","unstructured":"Nimako, M., A. N. Fiander, G. W. Wilkinson, L. K. Borysiewicz, and S. Man. 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res.57:4855-4861.","journal-title":"Cancer Res."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","year":"2007","unstructured":"Paavonen, J., D. Jenkins, F. X. Bosch, P. Naud, J. Salmer\u00f3n, C. M. Wheeler, S. N. Chow, D. L. Apter, H. C. Kitchener, X. Castellsague, N. S. de Carvalho, S. R. Skinner, D. M. Harper, J. A. Hedrick, U. Jaisamrarn, G. A. Limson, M. Dionne, W. Quint, B. Spiessens, P. Peeters, F. Struyf, S. L. Wieting, M. O. Lehtinen, and G. Dubin for the HPV PATRICIA study group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet369:2161-2170.","journal-title":"Lancet"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.154.11.5934","volume":"154","year":"1995","unstructured":"Ressing, M. E., A. Sette, R. M. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol.154:5934-5943.","journal-title":"J. Immunol."},{"key":"e_1_3_2_27_2","first-page":"582","volume":"56","year":"1996","unstructured":"Ressing, M. E., W. J. van Driel, E. Celis, A. Sette, M. P. Brandt, M. Hartman, J. D. Anholts, G. M. Schreuder, W. B. ter Harmsel, G. J. Fleuren, B. J. Trimbos, W. M. Kast, and C. J. Melief. 1996. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res.56:582-588.","journal-title":"Cancer Res."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","volume":"26","year":"2008","unstructured":"Schiller, J. T., X. Castellsague, L. L. Villa, and A. Hildesheim. 2008. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine26(Suppl.):K53-K61.","journal-title":"Vaccine"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","year":"2007","unstructured":"Smith, J. S., L. Lindsay, B. Hoots, J. Keys, S. Franceschi, R. Winer, and G. M. Clifford. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta analysis update. Int. J. Cancer121:621-632.","journal-title":"Int. J. Cancer"},{"key":"e_1_3_2_30_2","first-page":"167","volume":"17","year":"2005","unstructured":"Smith, K. L., A. Tristram, K. M. Gallagher, A. N. Fiander, and S. Man. 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int. Immunol.17:167-176.","journal-title":"Int. Immunol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","volume":"93","year":"2005","unstructured":"Steele, J. C., C. H. Mann, S. Rookes, T. Rollason, D. Murphy, M. G. Freeth, P. H. Gallimore, and S. Roberts. 2005. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br. J. Cancer93:248-259.","journal-title":"Br. J. Cancer"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2004.08.052","volume":"96","year":"2005","unstructured":"Valdespino, V., C. Gorodezky, V. Ortiz, A. M. Kaufmann, E. Roman-Basaure, A. Vazquez, and J. Berumen. 2005. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol. Oncol.96:92-102.","journal-title":"Gynecol. Oncol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1119>3.0.CO;2-C","volume":"91","year":"2001","unstructured":"van der Burg, S. H., M. E. Ressing, K. M. Kwappenberg, A. de Jong, K. Straathof, J. de Jong, A. Geluk, K. E. van Meijgaarden, K. L. Franken, T. H. Ottenhoff, G. J. Fleuren, G. Kenter, C. J. Melief, and R. Offringa. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer.91:612-618.","journal-title":"Int. J. Cancer."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","year":"1999","unstructured":"Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Mu\u00f1oz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189:12-19.","journal-title":"J. Pathol."},{"key":"e_1_3_2_35_2","first-page":"636","volume":"63","year":"2003","unstructured":"Welters, M. J., A. de Jong, S. J. van den Eeden, J. M. van der Hulst, K. M. Kwappenberg, S. Hassane, K. L. Franken, J. W. Drijfhout, G. J. Fleuren, G. Kenter, C. J. Melief, R. Offringa, and S. H. van der Burg. 2003. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res.63:636-641.","journal-title":"Cancer Res."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-07-1880","volume":"14","year":"2008","unstructured":"Welters, M. J., G. G. Kenter, S. J. Piersma, A. P. Vloon, M. J. L\u00f6wik, D. M. Berends-van der Meer, J. W. Drijfhout, A. R. Valentijn, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, R. Offringa, C. J. Melief, and S. H. van der Burg. 2008. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res.14:178-187.","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_37_2","first-page":"133","volume":"1","year":"2010","unstructured":"Woo, Y. L., M. van den Hende, J. C. Sterling, N. Coleman, R. A. Crawford, K. M. Kwappenberg, M. A. Stanley, and S. H. van der Burg. 2010. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int. J. Cancer1:133-141.","journal-title":"Int. J. Cancer"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","year":"2002","unstructured":"zur Hausen, H. 2002. Papillomavirus and cancer: from basic studies to clinical application. Nat. Rev. Cancer2:342-350.","journal-title":"Nat. Rev. Cancer"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00105-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00105-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T12:44:26Z","timestamp":1685709866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00105-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1128\/CVI.00105-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00105-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"2010-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}